| __timestamp | Iovance Biotherapeutics, Inc. | Johnson & Johnson |
|---|---|---|
| Wednesday, January 1, 2014 | 2704597 | 8494000000 |
| Thursday, January 1, 2015 | 15470000 | 9046000000 |
| Friday, January 1, 2016 | 28037000 | 9095000000 |
| Sunday, January 1, 2017 | 71615000 | 10554000000 |
| Monday, January 1, 2018 | 99828000 | 10775000000 |
| Tuesday, January 1, 2019 | 166023000 | 11355000000 |
| Wednesday, January 1, 2020 | 201727000 | 12340000000 |
| Friday, January 1, 2021 | 259039000 | 14277000000 |
| Saturday, January 1, 2022 | 294781000 | 14135000000 |
| Sunday, January 1, 2023 | 344077000 | 15048000000 |
| Monday, January 1, 2024 | 17232000000 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology and pharmaceuticals, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Johnson & Johnson and Iovance Biotherapeutics, Inc. have demonstrated contrasting approaches to R&D investment.
From 2014 to 2023, Johnson & Johnson consistently allocated substantial resources to R&D, with expenditures growing from approximately $8.5 billion to $15 billion, marking a 76% increase. This commitment underscores their strategy to maintain a competitive edge in the global market.
Conversely, Iovance Biotherapeutics, Inc., a smaller player, has shown a remarkable 12,600% increase in R&D spending, from $2.7 million in 2014 to $344 million in 2023. This aggressive investment reflects their focus on pioneering breakthroughs in cancer immunotherapy.
These trends highlight the diverse strategies companies employ to drive innovation and secure their future in the industry.
Who Prioritizes Innovation? R&D Spending Compared for Johnson & Johnson and Biogen Inc.
R&D Insights: How Johnson & Johnson and Ionis Pharmaceuticals, Inc. Allocate Funds
Johnson & Johnson or Arrowhead Pharmaceuticals, Inc.: Who Invests More in Innovation?
R&D Insights: How Novartis AG and Iovance Biotherapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for ADMA Biologics, Inc. and Iovance Biotherapeutics, Inc.
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Iovance Biotherapeutics, Inc.
Comparing Innovation Spending: PTC Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
R&D Spending Showdown: Catalyst Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
Research and Development Investment: Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
Analyzing R&D Budgets: Iovance Biotherapeutics, Inc. vs Novavax, Inc.
R&D Spending Showdown: Iovance Biotherapeutics, Inc. vs MiMedx Group, Inc.